Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerrit Los

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Bioorganic & Medicinal Chemistry Letters|September 5, 2009
Structure-based design of novel human Pin1 inhibitors (I)Chuangxing Guo, Xinjun Hou, Liming Dong, et al.
Molecular Cancer Therapeutics|March 6, 2012
Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitorHelen Y Zou, Qiuhua Li, Joseph H Lee, et al.
Cancer Research|May 8, 2007
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanismsHelen Y Zou, Qiuhua Li, Joseph H Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2010
PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activityCathy C Zhang, Zhengming Yan, Qin Zhang, et al.
Molecular Cancer Therapeutics|June 5, 2013
Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancerMaike Ihnen, Christine zu Eulenburg, Teodora Kolarova, et al.
Molecular Cancer Therapeutics|April 1, 2010
PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapyJitesh P Jani, Joel Arcari, Vincent Bernardo, et al.
Journal of Medicinal Chemistry|September 23, 2011
Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonistsChuangxing Guo, Angelica Linton, Susan Kephart, et al.
Nature Communications|January 17, 2025
RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemiaTim Kong, Angelo B A Laranjeira, Christopher T Letson, et al.
Mabs|September 26, 2012
Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621Neil R Michaud, Jitesh P Jani, Stephen Hillerman, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Bioorganic & Medicinal Chemistry Letters|September 5, 2009
Structure-based design of novel human Pin1 inhibitors (I)Chuangxing Guo, Xinjun Hou, Liming Dong, et al.
Molecular Cancer Therapeutics|March 6, 2012
Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitorHelen Y Zou, Qiuhua Li, Joseph H Lee, et al.
Cancer Research|May 8, 2007
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanismsHelen Y Zou, Qiuhua Li, Joseph H Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2010
PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activityCathy C Zhang, Zhengming Yan, Qin Zhang, et al.
Molecular Cancer Therapeutics|June 5, 2013
Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancerMaike Ihnen, Christine zu Eulenburg, Teodora Kolarova, et al.
Molecular Cancer Therapeutics|April 1, 2010
PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapyJitesh P Jani, Joel Arcari, Vincent Bernardo, et al.
Journal of Medicinal Chemistry|September 23, 2011
Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonistsChuangxing Guo, Angelica Linton, Susan Kephart, et al.
Nature Communications|January 17, 2025
RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemiaTim Kong, Angelo B A Laranjeira, Christopher T Letson, et al.
Mabs|September 26, 2012
Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621Neil R Michaud, Jitesh P Jani, Stephen Hillerman, et al.
Pageof 3